Treatment outcomes and prevention of variceal bleeding in the esophagus and stomach in patients treated for chronic hepatitis C
DOI:
https://doi.org/10.15574/PS.2025.1(86).4552Keywords:
chronic hepatitis C, endovascular splenic artery embolization, secondary prophylaxis, variceal bleeding, esophagus, portal hypertension, splenomegaly, thrombocytopeniaAbstract
In patients with chronic hepatitis C (CHC) who have achieved a sustained virological response (SVR), the risk of developing clinically significant portal hypertension (CSPH) persists. It may be complicated by variceal bleeding (VB) from the gastroesophageal varices, which is associated with high mortality. The development of effective secondary prevention strategies is a relevant scientific challenge with significant practical and social value.
Aim - to evaluate the safety and effectiveness of endovascular splenic artery embolization (SAE) as a method of secondary prophylaxis in patients with CSPH after CHC treatment.
Materials and methods. The study involved 34 patients with ≥1 episode of esophageal VB who underwent SAE. We assessed safety and efficacy (based on bleeding recurrence), as well as hematological, biochemical, and ultrasonographic parameters before SAE and at a 12-month follow-up. Liver function was evaluated using Child-Pugh and MELD scores. All patients received standard-dose nonselective beta-blockers (NSBBs) and ursodeoxycholic acid.
Results. No deaths occurred within 12 months post-SAE. The recurrence rate decreased tenfold (from 2.71 to 0.26 episodes per patient). Spleen volume decreased from 811 cm³ to 479 cm³; platelet count increased (from 78.5 to 143)×10³/µL; hemoglobin and thrombocrit levels also improved. Child-Pugh and MELD scores showed positive dynamics.
Conclusions. In patients successfully treated for CHC, the risk of progression of portal hypertension and the occurrence of life-threatening complications in the form of VB is not eliminated. SAE is a safe and effective method for secondary prevention of VB in patients with CHC who have achieved SVR.
The study was conducted in accordance with the principles of the Declaration of Helsinki. The study protocol was approved by the Local Ethics Committee for all participants. Informed consent was obtained from patients.
The authors declare no conflict of interest.
References
De Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C et al. (2022, Apr). Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 76(4): 959-974. Epub 2021 Dec 30. doi: 10.1016/j.jhep.2021.12.022. Erratum in: J Hepatol. 2022 Jul; 77(1): 271. https://doi.org/10.1016/j.jhep.2022.03.024; PMid:35431106
Fleckenstein FN, Luedemann WM, Kücükkaya A, Auer TA, Plewe J, Hamm B et al. (2022, Mar 10). Günther RW, Fehrenbach U, Gebauer B, Wieners G. Splenic artery steal syndrome in patients with orthotopic liver transplant: Where to embolize the splenic artery? PLoS One. 17(3): e0263832. https://doi.org/10.1371/journal.pone.0263832 ;PMid:35271572 PMCid:PMC8912229
Funes FR, da Silva RCMA, Arroyo Jr PC, Duca WJ, da Silva AAM, da Silva RF. Mortality and complications in patients with portal hypertension who underwent transjugular intrahepatic portosystemic shunt (TIPS) - 12 years experience. Arq. Gastroenterol. 49(2). https://doi.org/10.1590/S0004-28032012000200009; PMid:22767002
Ghany MG, Morgan TR; AASLD-IDSA Hepatitis C Guidance Panel. (2020, Feb). Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 71(2): 686-721. https://doi.org/10.1002/hep.31060; PMid:31816111 PMCid:PMC9710295
Kanda Y. (2013). Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 48: 452-458. https://doi.org/10.1038/bmt.2012.244; PMid:23208313 PMCid:PMC3590441
Kozlov S. (2024). Clinical Implementation of SAE in Patients with Portal Hypertension. Wiad Lek. 77(5): 108-114. https://doi.org/10.36740/WLek202405108; PMid:39008579
Reiberger T, Hofer BS. (2023). The Baveno VII concept of cirrhosis recompensation. Digestive and Liver Disease. 55(4): 431-441. https://doi.org/10.1016/j.dld.2022.12.014; PMid:36646527
Van der Meer AJ, Feld JJ, Hofer H, Almasio PL, Calvaruso V, Fernández-Rodríguez CM et al. (2017, Mar). Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol. 66(3): 485-493. Epub 2016 Oct 22. https://doi.org/10.1016/j.jhep.2016.10.017; PMid:27780714
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Paediatric Surgery (Ukraine)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The policy of the Journal “PAEDIATRIC SURGERY. UKRAINE” is compatible with the vast majority of funders' of open access and self-archiving policies. The journal provides immediate open access route being convinced that everyone – not only scientists - can benefit from research results, and publishes articles exclusively under open access distribution, with a Creative Commons Attribution-Noncommercial 4.0 international license(СС BY-NC).
Authors transfer the copyright to the Journal “PAEDIATRIC SURGERY.UKRAINE” when the manuscript is accepted for publication. Authors declare that this manuscript has not been published nor is under simultaneous consideration for publication elsewhere. After publication, the articles become freely available on-line to the public.
Readers have the right to use, distribute, and reproduce articles in any medium, provided the articles and the journal are properly cited.
The use of published materials for commercial purposes is strongly prohibited.
